Orphanet: Wyszukaj badanie kliniczne

Wyszukaj badanie kliniczne

152 Wyniki

Krajowe badania kliniczne

Treatment of inflammation inside the eye caused by an overactive immune system (autoimmune uveitis) using adalimumab Bristol Royal Infirmary Bristol Clinical Trials Centre

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - AU Institution: Information not provided - AU

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation (Phase 1-2) - AT Institution: Information not provided - AT

LINNAEA: A Phase 2 Trial of the Efficacy and Safety of the Interleukin-17A Inhibitor ABY-035 in the Treatment and Prevention of Relapse/Recurrence of Non-infectious Intermediate, Posterior or Pan-uveitis, Including an Initial Pilot Phase - AT Institution: Information not provided - AT

MYCUV-IIT02: Myfortic (Magensaftresistente Mycophenolat-Natrium) zur Behandlung der nicht-infektiöser, intermediärer Uveitis - eine prospektive, kontrollierte, randomisierte multizentrische Studie (Phase III) Department für Augenheilkunde Tübingen Universitäts-Augenklinik

Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase-2b-Studie von RVT-1401 zur Behandlung von Patienten mit aktiver, mittelschwerer bis schwerer Ophthalmopathie Graves Bürgerhospital Frankfurt am Main Orbitazentrum

Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase-2b-Studie von RVT-1401 zur Behandlung von Patienten mit aktiver, mittelschwerer bis schwerer Ophthalmopathie Graves Augenklinik des UKGM am Standort Gießen Klinik und Poliklinik für Augenheilkunde

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - PT Institution: Information not provided - PT

A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis -GB Institution: Information not provided - US

Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (Phase III) - AT St. Anna Kinderspital Zentrum für Kinder- und Jugendheilkunde

Translational stem cell research in ophthalmology - regenerating the anterior cornea through standardized transplantation of limbal epithelial stem cells: a phase II multicenter trial University Hospital Antwerp - UZA Antwerp University Hospital

Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (Phase III) - FR CLCC Institut Curie Institut Curie

Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial - FR Hôpital Necker-Enfants Malades Service de Génétique Moléculaire

Ensayo Multinacional Europeo para niños con el Síndrome de Opsoclono Mioclono / Síndrome del Ojo Danzante SOM/SOD Hospital Clínico Universitario Virgen de la Arrixaca Servicio de Oncohematología Pediátrica

Neurofeedback for Patients With Visual Snow UniversitätsSpital Zürich Research at the Department of Neuroradiology

UMSCOM: Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (phase III) - UK John Radcliffe Hospital Department of Paediatrics

COMINO: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion - AT Medizinische Universität Graz Universitäts-Augenklinik

PASSPORT: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy (Phase 2) - AT Institution: Information not provided - AT

RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (Phase 3) - AT Institution: Information not provided - AT

FIREFLEYE: Open-label, Randomized, Two-Arm, Controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal (IVT) Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (ROP) (Phase 3) - AT Institution: Information not provided - AT

FIREFLEYE next: An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090 (Phase 3) - AT Institution: Information not provided - AT

Accelerated Corneal Cross-linking With Different Riboflavin Solutions (phase 3) Allgemeines Krankenhaus der Stadt Wien Universitätsklinik für Augenheilkunde und Optometrie

Correlation Between In-vivo Anatomy of Corneal Dystrophies as Assessed by High-Resolution Optical Coherence Tomography (OCT) Measurement and Histological Examination - A Pilot Study Allgemeines Krankenhaus der Stadt Wien Universitätsklinik für klinische Pharmakologie

HLA A29 studie: Abatacept bij patiënten met Birdshot HLA A29 Uveïtis: een fase II-prospectieve open-label interventionele proof-of-concept studie UZ Leuven - Campus Gasthuisberg Dienst oogziekten/Ophthalmology

An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein-1 (REP1) (Phase I) University of Alberta CHM

TELeMAC: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 CLCC Georges François Leclerc Centre de Recherche Clinique (CRC)

PNPRO-HC : Essai de prévention de la non-perfusion rétinienne au cours des occlusions de veine centrale rétinienne par traitement à l'hydroxycarbamide (Phase II) Centre hospitalier national d'ophtalmologie des Quinze-Vingts Centre de Référence REFERET

RITUX-MMP : Essai clinique randomisé, en double aveugle, comparant l'efficacité et la tolérance du Rituximab versus la Cyclophosphamide dans les formes sévères de Pemphigoïdes des membranes muqueuses (Phase III) CHU de Rouen Clinique dermatologique

PEMPA : Etude de la pharmacocinétique de l'acide mycophénolique chez les patients atteints de dermatose bulleuse auto-immune (pemphigus et pemphigoïde cicatricielle) (Phase III) CHU de Bordeaux - Hôpital Saint André Service de Dermatologie adulte et pédiatrique

Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus (Phase III) - FR CHU de Toulouse - Hôpital Purpan Département génétique - maladies humaines et modèles animaux

IRIS 2: Compensation de la cécité à l'aide du système d'implant rétinien intelligent (IRIS V2) chez des patients atteints de dystrophie rétinienne. CHU de Nantes - Hôtel Dieu Service d'ophtalmologie

THOR: Klinische Phase II-Studie zur Gentherapie bei Patienten mit Chorioideremie mittels adeno-assoziierter viraler Vektoren (This study is enrolling participants by invitation only) Department für Augenheilkunde Tübingen Universitäts-Augenklinik

ROPROP: Orales Propranolol zur Prävention einer höhergradigen Frühgeborenen-Retinopathie -DE- Charité - Universitätsmedizin Berlin (CCM) Klinik für Neonatologie

IRIS 2: Behandlung von Blindheit mit dem intelligenten Netzhautimplantatsystem (IRISV2) bei Patienten mit Netzhautdystrophie Universitäts-Augenklinik Bonn

CoRaLa_II: Langzeitbedarf von Ranibizumab-Injektionen mit oder ohne frühzeitige gezielte peri-phere Laser-Photokoagulation zur Behandlung des Makulaödems infolge eines Zentralvenenverschlusses Universität-Augenklinik Leipzig Klinik und Poliklinik für Augenheilkunde

Studio multicentrico sull'efficacia del trattamento con Ciclosporina A in collirio in pazienti affetti da Cheratocongiuntivite primaverile Policlinico Universitario Campus Bio-Medico Dipartimento di Oftalmologia

SPECTRA studie: Studie naar halve dosis fotodynamische therapie versus eplerenon bij chronische centrale sereuze chorioretinopathie (fase IV) LUMC - Leids Universitair Medisch Centrum Afdeling Oogheelkunde

ELIKIDS: Estudio abierto, de dos cohortes (con y sin imiglucerasa) y multicéntrico para evaluar la farmacocinética (FC), seguridad y eficacia de eliglustat en pacientes pediátricos con enfermedad de Gaucher (EG) tipo 1 (EG1) y tipo 3 (EG3) Institution: Information not provided - ES

FIREFLEYE next: Estudio de extensión para evaluar los resultados a largo plazo de los pacientes que recibieron tratamiento para la retinopatía del prematuro en el ensayo 20090 - ES Institution: Information not provided - ES

DonnaMega - A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity - SE University of Gothenburg Department of clinical neurosciences

Cross Sectional Study: in Vivo Morphometric Characterisation of Human Retinal Pigment Epithelium With Transscleral Optical Phase Imaging in Photoreceptor/ Retinal Pigment Epithelium/ Bruch's Membrane/ Choriocapillaris Complex Disorders Luzerner Kantonsspital

A Study to Test the Potential of Brillouin Microscopy for Biomechanical Properties Measurements in Human Cornea IROC AG Institut für Refraktive und Ophthalmo-Chirurgie (IROC)

ROPROP: Oral Propranolol for prevention of thresholdretinopathy of prematurity - CH Universitätspital Zürich Klinik für Neonatologie

An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1) Moorfield's Eye Hospital

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis Moorfield's Eye Hospital

An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1) Le Gros Clark Building - University of Oxford Neuroscience

STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia - US PTC Therapeutics Inc.

A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) - AT Medizinische Universität Innsbruck Universitätsklinik für Neurologie

LEROS: External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) (Phase 4) - AT Institution: Information not provided - AT

A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) - AT Institution: Information not provided - AT

Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica (Phase I-II) University of Calgary Hotchkiss Brain Institute

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult (EE) West Tallinn Central Hospital Neurology Clinic

Etude randomisée, en double aveugle, controllée par placebo, multicentrique, pour évaluer l'éfficacité et la tolérance de l'Eculizumab chez dzs patients présentants une récidive de neuromyélite optique (NMO) (Phase III) Institution: Information not provided - FR

RIVA-PSP : Etude randomisée, en double aveugle vs placebo de l'efficacité de la RIVAstigmine sur les troubles moteurs et cognitivo-comportementaux dans la Paralysie Supranucléaire Progressive (Phase III) CHU de Marseille - Hôpital de la Timone Service de Neurologie, pathologie du mouvement

RESCUE/REVERSE: Langfristiges Follow-up von ND4 LHON Probanden, die mit GS010 okulärer Gentherapie in der RESCUE oder REVERSE Phase III Klinischen Studien behandelt wurden Friedrich-Baur-Institut Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik

Eine offene, einarmige Phase 2/3-Studie zur Bewertung der Sicherheit und Aktivität von Eculizumab bei pädiatrischen Patienten mit rezidivierenden Neuromyelitis-optica-Spektrum-Erkrankungen Institution: Information not provided - DE

Eine multizentrische, einarmige, offene Studie zur Evaluierung der langfristigen Sicherheit und Wirksamkeit von Satralizumab bei Patienten mit Neuromyelitis-optica-Spektrum-Störung (NMOSD) Ruhr-Universität Bochum

PREVENT: Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische Phase-III-Studie zur Beurteilung der Sicherheit und Wirksamkeit von Eculizumab bei Patienten mit rezidivierender Neuromyelitis optica Universitätsklinikum Düsseldorf Neuromyelitis optica Studiengruppe (NEMOS)

Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase 3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von SA237 plus Basistherapie bei Patienten mit Neuromyelitis optica und NMO-Spektrum-Krankheit Universitätsklinikum Düsseldorf

A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) -HU Jahn Ferenc Del-pesti Korhaz es Rendelointezet

Ensayo en fase II/III abierto, de un solo grupo para evaluar la seguridad y la actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante Hospital Universitario Virgen Macarena Unidad de Neurología y Neurofisiología

Ensayo en fase II/III abierto, de un solo grupo para evaluar la seguridad y la actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante Hospital Sant Joan de Déu Barcelona Unidad de Neuroinmunología

Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (NMOSD) Institution: Information not provided - ES

Estudio abierto, multicéntrico y de un solo grupo para evaluar la seguridad y la eficacia a largo plazo de satralizumab (SA237) en pacientes con un trastorno del espectro de la neuromielitis óptica (TENMO) Institution: Information not provided - ES

Estudio de extensión de etiqueta abierta para evaluar la seguridad y la tolerabilidad de la administración a largo plazo de UCB0107 en participantes del estudio con parálisis supranuclear progresiva Institution: Information not provided - ES

Setmelanotide (RM-493): Ensayo de tratamiento en fase 2 de Setmelanotida (RM-493) en pacientes con trastornos genéticos raros de obesidad Hospital Infantil Universitario Niño Jesús Servicio de Endocrinología, Crecimiento y Metabolismo

LEROS: Estudio de intervención abierto controlado por grupo de evolución natural externo para evaluar la eficacia y la seguridad del tratamiento prolongado con Raxone® en la neuropatía óptica hereditaria de Leber (NOHL) Hospital Universitario Ramón y Cajal Servicio de Oftalmología

REFLECT: Ensayo aleatorizado, con doble enmascaramiento y controlado con placebo en sujetos afectados con Neuropatía óptica hereditaria de Leber G11778A ND4 desde hace un año Hospital Universitario Ramón y Cajal Servicio de Oftalmología

A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of SA237 in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) - UK Hoffmann-La Roche Hoffmann - La Roche Ltd.

RESCUE/REVERSE: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials-GB Moorfield's Eye Hospital

A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) - UK The Walton Centre NHS Foundation Trust The Walton Centre NHS Foundation Trust HQ

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity University Hospital Birmingham Marshfield Clinic

OPA1: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation Medizinische Universität Graz Universitäts-Augenklinik

STELLAR: Een studie om de veiligheid en verdraagbaarheid van QR-421a te evalueren voor de eerste maal bij personen met retinitis pigmentosa (RP) als gevolg van mutaties in Exon 13 van het USH2A-gen -BE Ghent University Hospital - UZ Gent Department of Ophthalmology/Dienst Oogheelkunde - UZ Gent

De ADVISE-studie: geavanceerde visualisatie bij corneachirurgie evaluatie intra-operatieve optische coherentietomografie in posterieure lamellaire keratoplastiek - BE UZ Leuven - Campus Gasthuisberg Dienst oogziekten/Ophthalmology

Etude d'escalade de dose de phase I/IIa évaluant la sécurité de l'injection subrétinienne de SAR422459 chez les patients atteints de la maladie de Stargardt - FR Centre hospitalier national d'ophtalmologie des Quinze-Vingts Centre de Référence REFERET

STELLAR: étude d'évaluation de l'innocuité et de la tolérabilité de QR-421a chez des sujets présentant une RP dûe aux mutations de l'exon 13 du gène USH2A Centre hospitalier national d'ophtalmologie des Quinze-Vingts Centre de Référence REFERET

Treatment of inflammation inside the eye caused by an overactive immune system (autoimmune uveitis) using adalimumab
Bristol Royal Infirmary

Bristol Clinical Trials Centre

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - AU
Institution: Information not provided - AU

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation (Phase 1-2) - AT
Institution: Information not provided - AT

LINNAEA: A Phase 2 Trial of the Efficacy and Safety of the Interleukin-17A Inhibitor ABY-035 in the Treatment and Prevention of Relapse/Recurrence of Non-infectious Intermediate, Posterior or Pan-uveitis, Including an Initial Pilot Phase - AT
Institution: Information not provided - AT

MYCUV-IIT02: Myfortic (Magensaftresistente Mycophenolat-Natrium) zur Behandlung der nicht-infektiöser, intermediärer Uveitis - eine prospektive, kontrollierte, randomisierte multizentrische Studie (Phase III)
Department für Augenheilkunde Tübingen

Universitäts-Augenklinik

Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase-2b-Studie von RVT-1401 zur Behandlung von Patienten mit aktiver, mittelschwerer bis schwerer Ophthalmopathie Graves
Bürgerhospital Frankfurt am Main

Orbitazentrum

Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase-2b-Studie von RVT-1401 zur Behandlung von Patienten mit aktiver, mittelschwerer bis schwerer Ophthalmopathie Graves
Augenklinik des UKGM am Standort Gießen

Klinik und Poliklinik für Augenheilkunde

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - PT
Institution: Information not provided - PT

A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis -GB
Institution: Information not provided - US

Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (Phase III) - AT
St. Anna Kinderspital

Zentrum für Kinder- und Jugendheilkunde

Translational stem cell research in ophthalmology - regenerating the anterior cornea through standardized transplantation of limbal epithelial stem cells: a phase II multicenter trial
University Hospital Antwerp - UZA

Antwerp University Hospital

Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (Phase III) - FR
CLCC Institut Curie

Institut Curie

Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial - FR
Hôpital Necker-Enfants Malades

Service de Génétique Moléculaire

Ensayo Multinacional Europeo para niños con el Síndrome de Opsoclono Mioclono / Síndrome del Ojo Danzante SOM/SOD
Hospital Clínico Universitario Virgen de la Arrixaca

Servicio de Oncohematología Pediátrica

Neurofeedback for Patients With Visual Snow
UniversitätsSpital Zürich

Research at the Department of Neuroradiology

UMSCOM: Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (phase III) - UK
John Radcliffe Hospital

Department of Paediatrics

COMINO: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion - AT
Medizinische Universität Graz

Universitäts-Augenklinik

PASSPORT: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy (Phase 2) - AT
Institution: Information not provided - AT

RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (Phase 3) - AT
Institution: Information not provided - AT

FIREFLEYE: Open-label, Randomized, Two-Arm, Controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal (IVT) Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (ROP) (Phase 3) - AT
Institution: Information not provided - AT

FIREFLEYE next: An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090 (Phase 3) - AT
Institution: Information not provided - AT

Accelerated Corneal Cross-linking With Different Riboflavin Solutions (phase 3)
Allgemeines Krankenhaus der Stadt Wien

Universitätsklinik für Augenheilkunde und Optometrie

Correlation Between In-vivo Anatomy of Corneal Dystrophies as Assessed by High-Resolution Optical Coherence Tomography (OCT) Measurement and Histological Examination - A Pilot Study
Allgemeines Krankenhaus der Stadt Wien

Universitätsklinik für klinische Pharmakologie

HLA A29 studie: Abatacept bij patiënten met Birdshot HLA A29 Uveïtis: een fase II-prospectieve open-label interventionele proof-of-concept studie
UZ Leuven - Campus Gasthuisberg

Dienst oogziekten/Ophthalmology

An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein-1 (REP1) (Phase I)
University of Alberta

CHM

TELeMAC: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
CLCC Georges François Leclerc

Centre de Recherche Clinique (CRC)

PNPRO-HC : Essai de prévention de la non-perfusion rétinienne au cours des occlusions de veine centrale rétinienne par traitement à l'hydroxycarbamide (Phase II)
Centre hospitalier national d'ophtalmologie des Quinze-Vingts

Centre de Référence REFERET

RITUX-MMP : Essai clinique randomisé, en double aveugle, comparant l'efficacité et la tolérance du Rituximab versus la Cyclophosphamide dans les formes sévères de Pemphigoïdes des membranes muqueuses (Phase III)
CHU de Rouen

Clinique dermatologique

PEMPA : Etude de la pharmacocinétique de l'acide mycophénolique chez les patients atteints de dermatose bulleuse auto-immune (pemphigus et pemphigoïde cicatricielle) (Phase III)
CHU de Bordeaux - Hôpital Saint André

Service de Dermatologie adulte et pédiatrique

Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus (Phase III) - FR
CHU de Toulouse - Hôpital Purpan

Département génétique - maladies humaines et modèles animaux

IRIS 2: Compensation de la cécité à l'aide du système d'implant rétinien intelligent (IRIS V2) chez des patients atteints de dystrophie rétinienne.
CHU de Nantes - Hôtel Dieu

Service d'ophtalmologie

THOR: Klinische Phase II-Studie zur Gentherapie bei Patienten mit Chorioideremie mittels adeno-assoziierter viraler Vektoren (This study is enrolling participants by invitation only)
Department für Augenheilkunde Tübingen

Universitäts-Augenklinik

ROPROP: Orales Propranolol zur Prävention einer höhergradigen Frühgeborenen-Retinopathie -DE-
Charité - Universitätsmedizin Berlin (CCM)

Klinik für Neonatologie

IRIS 2: Behandlung von Blindheit mit dem intelligenten Netzhautimplantatsystem (IRISV2) bei Patienten mit Netzhautdystrophie
Universitäts-Augenklinik Bonn

CoRaLa_II: Langzeitbedarf von Ranibizumab-Injektionen mit oder ohne frühzeitige gezielte peri-phere Laser-Photokoagulation zur Behandlung des Makulaödems infolge eines Zentralvenenverschlusses
Universität-Augenklinik Leipzig

Klinik und Poliklinik für Augenheilkunde

Studio multicentrico sull'efficacia del trattamento con Ciclosporina A in collirio in pazienti affetti da Cheratocongiuntivite primaverile
Policlinico Universitario Campus Bio-Medico

Dipartimento di Oftalmologia

SPECTRA studie: Studie naar halve dosis fotodynamische therapie versus eplerenon bij chronische centrale sereuze chorioretinopathie (fase IV)
LUMC - Leids Universitair Medisch Centrum

Afdeling Oogheelkunde

ELIKIDS: Estudio abierto, de dos cohortes (con y sin imiglucerasa) y multicéntrico para evaluar la farmacocinética (FC), seguridad y eficacia de eliglustat en pacientes pediátricos con enfermedad de Gaucher (EG) tipo 1 (EG1) y tipo 3 (EG3)
Institution: Information not provided - ES

FIREFLEYE next: Estudio de extensión para evaluar los resultados a largo plazo de los pacientes que recibieron tratamiento para la retinopatía del prematuro en el ensayo 20090 - ES
Institution: Information not provided - ES

DonnaMega - A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity - SE
University of Gothenburg

Department of clinical neurosciences

Cross Sectional Study: in Vivo Morphometric Characterisation of Human Retinal Pigment Epithelium With Transscleral Optical Phase Imaging in Photoreceptor/ Retinal Pigment Epithelium/ Bruch's Membrane/ Choriocapillaris Complex Disorders
Luzerner Kantonsspital

A Study to Test the Potential of Brillouin Microscopy for Biomechanical Properties Measurements in Human Cornea
IROC AG

Institut für Refraktive und Ophthalmo-Chirurgie (IROC)

ROPROP: Oral Propranolol for prevention of thresholdretinopathy of prematurity - CH
Universitätspital Zürich

Klinik für Neonatologie

An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Moorfield's Eye Hospital

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Moorfield's Eye Hospital

An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Le Gros Clark Building - University of Oxford

Neuroscience

STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia - US
PTC Therapeutics Inc.

A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) - AT
Medizinische Universität Innsbruck

Universitätsklinik für Neurologie

LEROS: External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) (Phase 4) - AT
Institution: Information not provided - AT

A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) - AT
Institution: Information not provided - AT

Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica (Phase I-II)
University of Calgary

Hotchkiss Brain Institute

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult (EE)
West Tallinn Central Hospital

Neurology Clinic

Etude randomisée, en double aveugle, controllée par placebo, multicentrique, pour évaluer l'éfficacité et la tolérance de l'Eculizumab chez dzs patients présentants une récidive de neuromyélite optique (NMO) (Phase III)
Institution: Information not provided - FR

RIVA-PSP : Etude randomisée, en double aveugle vs placebo de l'efficacité de la RIVAstigmine sur les troubles moteurs et cognitivo-comportementaux dans la Paralysie Supranucléaire Progressive (Phase III)
CHU de Marseille - Hôpital de la Timone

Service de Neurologie, pathologie du mouvement

RESCUE/REVERSE: Langfristiges Follow-up von ND4 LHON Probanden, die mit GS010 okulärer Gentherapie in der RESCUE oder REVERSE Phase III Klinischen Studien behandelt wurden
Friedrich-Baur-Institut

Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik

Eine offene, einarmige Phase 2/3-Studie zur Bewertung der Sicherheit und Aktivität von Eculizumab bei pädiatrischen Patienten mit rezidivierenden Neuromyelitis-optica-Spektrum-Erkrankungen
Institution: Information not provided - DE

Eine multizentrische, einarmige, offene Studie zur Evaluierung der langfristigen Sicherheit und Wirksamkeit von Satralizumab bei Patienten mit Neuromyelitis-optica-Spektrum-Störung (NMOSD)
Ruhr-Universität Bochum

PREVENT: Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische Phase-III-Studie zur Beurteilung der Sicherheit und Wirksamkeit von Eculizumab bei Patienten mit rezidivierender Neuromyelitis optica
Universitätsklinikum Düsseldorf

Neuromyelitis optica Studiengruppe (NEMOS)

Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase 3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von SA237 plus Basistherapie bei Patienten mit Neuromyelitis optica und NMO-Spektrum-Krankheit
Universitätsklinikum Düsseldorf

A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) -HU
Jahn Ferenc Del-pesti Korhaz es Rendelointezet

Ensayo en fase II/III abierto, de un solo grupo para evaluar la seguridad y la actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante
Hospital Universitario Virgen Macarena

Unidad de Neurología y Neurofisiología

Ensayo en fase II/III abierto, de un solo grupo para evaluar la seguridad y la actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante
Hospital Sant Joan de Déu Barcelona

Unidad de Neuroinmunología

Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (NMOSD)
Institution: Information not provided - ES

Estudio abierto, multicéntrico y de un solo grupo para evaluar la seguridad y la eficacia a largo plazo de satralizumab (SA237) en pacientes con un trastorno del espectro de la neuromielitis óptica (TENMO)
Institution: Information not provided - ES

Estudio de extensión de etiqueta abierta para evaluar la seguridad y la tolerabilidad de la administración a largo plazo de UCB0107 en participantes del estudio con parálisis supranuclear progresiva
Institution: Information not provided - ES

Setmelanotide (RM-493): Ensayo de tratamiento en fase 2 de Setmelanotida (RM-493) en pacientes con trastornos genéticos raros de obesidad
Hospital Infantil Universitario Niño Jesús

Servicio de Endocrinología, Crecimiento y Metabolismo

LEROS: Estudio de intervención abierto controlado por grupo de evolución natural externo para evaluar la eficacia y la seguridad del tratamiento prolongado con Raxone® en la neuropatía óptica hereditaria de Leber (NOHL)
Hospital Universitario Ramón y Cajal

Servicio de Oftalmología

REFLECT: Ensayo aleatorizado, con doble enmascaramiento y controlado con placebo en sujetos afectados con Neuropatía óptica hereditaria de Leber G11778A ND4 desde hace un año
Hospital Universitario Ramón y Cajal

Servicio de Oftalmología

A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of SA237 in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) - UK
Hoffmann-La Roche

Hoffmann - La Roche Ltd.

RESCUE/REVERSE: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials-GB
Moorfield's Eye Hospital

A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) - UK
The Walton Centre NHS Foundation Trust

The Walton Centre NHS Foundation Trust HQ

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham

Marshfield Clinic

OPA1: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation
Medizinische Universität Graz

Universitäts-Augenklinik

STELLAR: Een studie om de veiligheid en verdraagbaarheid van QR-421a te evalueren voor de eerste maal bij personen met retinitis pigmentosa (RP) als gevolg van mutaties in Exon 13 van het USH2A-gen -BE
Ghent University Hospital - UZ Gent

Department of Ophthalmology/Dienst Oogheelkunde - UZ Gent

De ADVISE-studie: geavanceerde visualisatie bij corneachirurgie evaluatie intra-operatieve optische coherentietomografie in posterieure lamellaire keratoplastiek - BE
UZ Leuven - Campus Gasthuisberg

Dienst oogziekten/Ophthalmology

Etude d'escalade de dose de phase I/IIa évaluant la sécurité de l'injection subrétinienne de SAR422459 chez les patients atteints de la maladie de Stargardt - FR
Centre hospitalier national d'ophtalmologie des Quinze-Vingts

Centre de Référence REFERET

STELLAR: étude d'évaluation de l'innocuité et de la tolérabilité de QR-421a chez des sujets présentant une RP dûe aux mutations de l'exon 13 du gène USH2A
Centre hospitalier national d'ophtalmologie des Quinze-Vingts

Centre de Référence REFERET

PIGMENT: PDE6A Gentherapie für Retinitis Pigmentosa (RD-Cure Gentherapie-Studie)
Department für Augenheilkunde Tübingen

Universitäts-Augenklinik

Primer estudio en humanos, de fase I/IIa, prospectivo, abierto, de la seguridad y tolerabilidad de células progenitoras de retina humana (hRPC) trasplantadas en el espacio subretiniano en sujetos con retinitis pigmentosa (RP)
Centro Médico Teknon - Grupo Quirónsalud

Institut de la Màcula

Estudio ADARET: Estudio de fase I, unicéntrico, aleatorizado de grupos paralelos para evaluar la seguridad y eficacia de la administración intravítrea de adalimumab en pacientes con retinosis pigmentaria
Hospital de Manises